These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

876 related items for PubMed ID: 26042589

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
    Blauvelt A, Sofen H, Papp K, Gooderham M, Tyring S, Zhao Y, Lowry S, Mendelsohn A, Parno J, Reich K.
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2305-2312. PubMed ID: 31407394
    [Abstract] [Full Text] [Related]

  • 43. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
    Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C, Macias W, Zhang X, Janes JM.
    Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
    [Abstract] [Full Text] [Related]

  • 44. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal.
    Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN.
    Br J Dermatol; 2019 Jun; 180(6):1348-1351. PubMed ID: 30632140
    [Abstract] [Full Text] [Related]

  • 45. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.
    Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M.
    Clin Exp Dermatol; 2022 Mar; 47(3):561-567. PubMed ID: 34642965
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm® - and placebo-controlled trial (BRIDGE).
    Mrowietz U, Szepietowski JC, Loewe R, van de Kerkhof P, Lamarca R, Ocker WG, Tebbs VM, Pau-Charles I.
    Br J Dermatol; 2017 Mar; 176(3):615-623. PubMed ID: 27515097
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A.
    Lancet; 2019 Sep 07; 394(10201):831-839. PubMed ID: 31402114
    [Abstract] [Full Text] [Related]

  • 50. Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS).
    Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Schäkel K, Wegner S, Krampe S, Bartz H, Rausch C, Taut F, Eyerich K.
    Br J Dermatol; 2024 Jun 20; 191(1):36-48. PubMed ID: 38133615
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
    Paller AS, Seyger MMB, Alejandro Magariños G, Bagel J, Pinter A, Cather J, Keller S, Rodriguez Capriles C, Gontijo Lima R, Gallo G, Little CA, Edson-Heredia E, Li L, Xu W, Papp K, IXORA-PEDS study group.
    Br J Dermatol; 2020 Aug 20; 183(2):231-241. PubMed ID: 32316070
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
    Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A, Efalizumab Study Group.
    Int J Dermatol; 2006 May 20; 45(5):605-14. PubMed ID: 16700803
    [Abstract] [Full Text] [Related]

  • 58. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
    Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, Guindon C, You R, Papavassilis C, JUNCTURE study group.
    J Eur Acad Dermatol Venereol; 2015 Jun 20; 29(6):1082-90. PubMed ID: 25243910
    [Abstract] [Full Text] [Related]

  • 59. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, UNCOVER-2 and UNCOVER-3 investigators.
    Lancet; 2015 Aug 08; 386(9993):541-51. PubMed ID: 26072109
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.